BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25667121)

  • 21. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.
    Du W; Wang S; Zhou Q; Li X; Chu J; Chang Z; Tao Q; Ng EK; Fang J; Sung JJ; Yu J
    Oncogene; 2013 Jul; 32(28):3319-28. PubMed ID: 22907434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
    Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
    Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pea3 expression promotes the invasive and metastatic potential of colorectal carcinoma.
    Mesci A; Taeb S; Huang X; Jairath R; Sivaloganathan D; Liu SK
    World J Gastroenterol; 2014 Dec; 20(46):17376-87. PubMed ID: 25516649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HOXB7 as a prognostic factor and mediator of colorectal cancer progression.
    Liao WT; Jiang D; Yuan J; Cui YM; Shi XW; Chen CM; Bian XW; Deng YJ; Ding YQ
    Clin Cancer Res; 2011 Jun; 17(11):3569-78. PubMed ID: 21474578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer.
    Yang M; Huang Q; Li C; Jiang Z; Sun J; Wang Z; Liang R; Li D; Li B; Zhao H
    Front Immunol; 2021; 12():647540. PubMed ID: 33897695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4.
    Wang J; Zhao X; Jin L; Wu G; Yang Y
    Dig Dis Sci; 2017 Oct; 62(10):2781-2789. PubMed ID: 28856538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Abnormal expression of APRIL in colorectal cancer cells promotes tumor growth and metastasis].
    Wang GH; Lu MH; Wang JC; Wang F; Ding WF; Wang YG; Ju SQ; Wang HM
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):249-55. PubMed ID: 23985251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
    Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
    J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model.
    Tang FY; Pai MH; Chiang EP
    J Nutr Biochem; 2012 Oct; 23(10):1302-13. PubMed ID: 22221675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling.
    Xu H; Sun H; Zhang H; Liu J; Fan F; Li Y; Ning X; Sun Y; Dai S; Liu B; Gao M; Fu S; Zhou C
    PLoS One; 2015; 10(5):e0124033. PubMed ID: 25962159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Odontogenic ameloblast-associated protein (ODAM) inhibits human colorectal cancer growth by promoting PTEN elevation and inactivating PI3K/AKT signaling.
    Yu M; Mu Y; Qi Y; Qin S; Qiu Y; Cui R; Zhong M
    Biomed Pharmacother; 2016 Dec; 84():601-607. PubMed ID: 27694004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
    Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
    Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.
    Iwaya T; Yokobori T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Sawada G; Takahashi Y; Ishibashi M; Wakabayashi G; Mori M; Mimori K
    Carcinogenesis; 2012 Dec; 33(12):2391-7. PubMed ID: 22983984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased expression of SCUBE2 is associated with progression and prognosis in colorectal cancer.
    Song Q; Li C; Feng X; Yu A; Tang H; Peng Z; Wang X
    Oncol Rep; 2015 Apr; 33(4):1956-64. PubMed ID: 25672935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of GRHL2 inhibited proliferation and induced apoptosis of colorectal cancer by suppressing the PI3K/Akt pathway.
    Hu F; He Z; Sun C; Rong D
    Gene; 2019 Jun; 700():96-104. PubMed ID: 30917932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
    Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
    Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition.
    Cheng XS; Li YF; Tan J; Sun B; Xiao YC; Fang XB; Zhang XF; Li Q; Dong JH; Li M; Qian HH; Yin ZF; Yang ZB
    Cancer Lett; 2014 Jun; 348(1-2):77-87. PubMed ID: 24657657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2.
    Liang L; Li X; Zhang X; Lv Z; He G; Zhao W; Ren X; Li Y; Bian X; Liao W; Liu W; Yang G; Ding Y
    Gastroenterology; 2013 Mar; 144(3):624-635.e4. PubMed ID: 23201162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR signaling pathway is a target for the treatment of colorectal cancer.
    Zhang YJ; Dai Q; Sun DF; Xiong H; Tian XQ; Gao FH; Xu MH; Chen GQ; Han ZG; Fang JY
    Ann Surg Oncol; 2009 Sep; 16(9):2617-28. PubMed ID: 19517193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression.
    Zhang Y; Li KF
    Biomed Pharmacother; 2019 Dec; 120():109127. PubMed ID: 31629952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.